HK1110802A1 - Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof - Google Patents

Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof

Info

Publication number
HK1110802A1
HK1110802A1 HK08105564.7A HK08105564A HK1110802A1 HK 1110802 A1 HK1110802 A1 HK 1110802A1 HK 08105564 A HK08105564 A HK 08105564A HK 1110802 A1 HK1110802 A1 HK 1110802A1
Authority
HK
Hong Kong
Prior art keywords
nucleic acids
medicament
preparation
composition
picornaviruses
Prior art date
Application number
HK08105564.7A
Other languages
English (en)
Inventor
Raymond Darren Shafren
Original Assignee
Viralytics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005900179A external-priority patent/AU2005900179A0/en
Application filed by Viralytics Ltd filed Critical Viralytics Ltd
Publication of HK1110802A1 publication Critical patent/HK1110802A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08105564.7A 2005-01-17 2008-05-20 Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof HK1110802A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005900179A AU2005900179A0 (en) 2005-01-17 Method and composition for treatment of neoplasms
PCT/AU2006/000051 WO2006074526A1 (en) 2005-01-17 2006-01-17 Method and composition for treatment of neoplasms

Publications (1)

Publication Number Publication Date
HK1110802A1 true HK1110802A1 (en) 2008-07-25

Family

ID=36677317

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08105564.7A HK1110802A1 (en) 2005-01-17 2008-05-20 Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof

Country Status (5)

Country Link
US (2) US20080160031A1 (zh)
EP (1) EP1843773A4 (zh)
CN (2) CN102166218A (zh)
HK (1) HK1110802A1 (zh)
WO (1) WO2006074526A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2441789B (en) * 2006-09-18 2012-03-28 Angus Buchan Gordon Use of a Tumour Volume Measuring Device
CN101368213A (zh) * 2008-10-13 2009-02-18 南京大学 血清微小核糖核酸试剂盒及其在乙肝早期诊断中的应用
IL206810A (en) * 2009-07-08 2015-07-30 Janssen Diagnostics Llc Methods for identifying melanoma and kits for using these methods
US9126966B2 (en) * 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
PL2826856T3 (pl) * 2013-07-16 2016-06-30 Sia Latima Genetycznie stabilny onkolityczny wirus RNA, sposób jego wytwarzania i zastosowanie
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
CN116904404A (zh) 2016-01-27 2023-10-20 昂克诺斯公司 溶瘤病毒载体及其用途
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP7249323B2 (ja) 2017-07-26 2023-03-30 オンコラス， インコーポレイテッド 腫瘍溶解性ウイルスベクター及びその使用
CN109419818B (zh) 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
CN111867609A (zh) * 2018-03-12 2020-10-30 梅约医学教育与研究基金会 用感染性核酸治疗癌症
WO2020102285A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20220117902A1 (en) * 2019-01-04 2022-04-21 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147822B1 (en) * 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
WO2002092132A2 (en) * 2001-01-05 2002-11-21 Corixa Corporation Microparticles and methods for delivery of recombinant viral vaccines
WO2002072027A2 (en) * 2001-03-14 2002-09-19 University Of Alabama Research Foundation Oncolytic rna replicons
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
ZA200608222B (en) * 2004-03-11 2008-07-30 Viralytics Ltd Modified oncolytic viruses

Also Published As

Publication number Publication date
US20080160031A1 (en) 2008-07-03
EP1843773A1 (en) 2007-10-17
CN101132798A (zh) 2008-02-27
EP1843773A4 (en) 2008-07-30
US20100104578A1 (en) 2010-04-29
WO2006074526A1 (en) 2006-07-20
CN101132798B (zh) 2011-04-27
CN102166218A (zh) 2011-08-31

Similar Documents

Publication Publication Date Title
HK1110802A1 (en) Use of nucleic acids in the preparation of a medicament for treating melanoma and the composition thereof
TW200611911A (en) Antibodies to erythropoietin receptor and uses thereof
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
EA201001639A1 (ru) Композиции и способы их получения и применения
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
TW200519202A (en) Modulation of eIF4E expression
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
HK1123733A1 (en) Viral hepatitis treatment
WO2005030121A3 (en) Compounds, compositions and methods
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
EA200900154A1 (ru) Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с
WO2007065010A3 (en) Anti-angiogenesis compounds
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
DE602005012276D1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MX2009003729A (es) Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
WO2007035771A3 (en) Modulation of glucagon receptor expression
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
TW200730518A (en) Crystalline forms of docetaxel and processes for their preparation
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
TW200734306A (en) Novel compounds, their preparation and use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200117